Free Trial
NASDAQ:CNSP

CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

CNS Pharmaceuticals logo
$7.70 -0.28 (-3.51%)
Closing price 08/1/2025 03:55 PM Eastern
Extended Trading
$8.04 +0.34 (+4.35%)
As of 08/1/2025 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CNS Pharmaceuticals Stock (NASDAQ:CNSP)

Key Stats

Today's Range
$7.70
$8.24
50-Day Range
$7.62
$13.20
52-Week Range
$7.50
$221.94
Volume
15,926 shs
Average Volume
29,429 shs
Market Capitalization
$3.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$300.00
Consensus Rating
Moderate Buy

Company Overview

CNS Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

CNSP MarketRank™: 

CNS Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CNS Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    CNS Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about CNS Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CNS Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CNS Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CNS Pharmaceuticals has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about CNS Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.93% of the outstanding shares of CNS Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CNS Pharmaceuticals has recently decreased by 92.18%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CNS Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    CNS Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.93% of the outstanding shares of CNS Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CNS Pharmaceuticals has recently decreased by 92.18%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 0.07% of the stock of CNS Pharmaceuticals is held by insiders.

    • Percentage Held by Institutions

      Only 14.02% of the stock of CNS Pharmaceuticals is held by institutions.

    • Read more about CNS Pharmaceuticals' insider trading history.
    Receive CNSP Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    CNSP Stock News Headlines

    Elon’s BIGGEST warning yet?
    Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
    See More Headlines

    CNSP Stock Analysis - Frequently Asked Questions

    CNS Pharmaceuticals' stock was trading at $72.24 on January 1st, 2025. Since then, CNSP shares have decreased by 89.3% and is now trading at $7.70.

    CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) announced its quarterly earnings data on Thursday, May, 15th. The company reported ($18.96) earnings per share (EPS) for the quarter.

    Shares of CNS Pharmaceuticals reverse split on Friday, February 21st 2025.The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

    CNS Pharmaceuticals (CNSP) raised $9 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO.

    Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and GE Aerospace (GE).

    Company Calendar

    Last Earnings
    5/15/2025
    Today
    8/02/2025
    Next Earnings (Estimated)
    8/13/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:CNSP
    CIK
    1729427
    Fax
    N/A
    Employees
    5
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $300.00
    Low Price Target
    $300.00
    Potential Upside/Downside
    +3,796.1%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.50
    Research Coverage
    2 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($3,748.50)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$14.86 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -385.41%
    Return on Assets
    -193.20%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    4.94
    Quick Ratio
    4.94

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $64.50 per share
    Price / Book
    0.12

    Miscellaneous

    Outstanding Shares
    450,000
    Free Float
    455,000
    Market Cap
    $3.47 million
    Optionable
    Not Optionable
    Beta
    2.64

    Social Links

    (Almost)  Everything You Need To Know About The EV Market Cover

    Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

    Get This Free Report

    This page (NASDAQ:CNSP) was last updated on 8/3/2025 by MarketBeat.com Staff
    From Our Partners